Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.
In: Contify Life Science News, 2023-12-21
Zeitungsartikel
Zugriff:
Titel: |
Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.
|
---|---|
Zeitschrift: | Contify Life Science News, 2023-12-21 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|